21 Ha’arba’a Street
Tel Aviv 6473921
Israel
972 3 541 3131
https://www.redhillbio.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 53
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Dror Ben-Asher | Co-Founder, Chairman & CEO | 594.61k | N/A | 1966 |
Mr. Razi Ingber | Chief Financial Officer | 339.82k | N/A | 1984 |
Mr. Gilead Raday MPhil, MSc | Chief Operating Officer | 365.56k | N/A | 1975 |
Mr. Adi Frish | Chief Corporate & Business Development Officer | 339.3k | N/A | 1970 |
Mr. Rick D. Scruggs | Chief Commercial Officer, President of RedHill Biopharma Inc. & Director | 469.8k | N/A | 1960 |
Ms. Alexandra Okmian | Senior Business Development & Investor Relations Manager | N/A | N/A | N/A |
Dr. Reza Fathi Ph.D. | Senior Vice President of Research & Development | 299.29k | N/A | 1955 |
Mr. Guy Goldberg J.D. | Chief Business Officer | 338.13k | N/A | 1976 |
Ms. Patricia Anderson B.Sc. RAC | Senior Vice President of Regulatory Affairs | N/A | N/A | N/A |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
RedHill Biopharma Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.